Dr. Reddy's Laboratories(NYSE: RDY) has launched Donepezil Hydrochloride Tablets, 23 mg, in the US market following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Donepezil Hydrochloride Tablets, 23 mg.
The new drug is therapeutic equivalent generic version of ARICEPT®, 23 mg. The ARICEPT®, 23 mg brand had US sales of approximately $92.6 million MAT for the most recent twelve months ending in May 2013, according to IMS Health.
Dr. Reddy's Donepezil Hydrochloride Tablets, 23 mg is available in bottle count sizes of 30 and 90. The company announced the approval of the new drugs in the US market on 27th July, 2013